1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-[4-(hydroxyl-methyl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-[4-(hydroxyl-methyl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide
• 英文别名: 1-[[5-chloro-2-(2-methylpropoxy)phenyl]methyl]-N-[4-(hydroxymethyl)phenyl]-5-methylpyrazole-3-carboxamide
• 化学式: C₂₃H₂₆ClN₃O₃
• 分子量: 427.931
• InChiKey: OKKQLAKSDOFDHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  76.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-[4-(hydroxyl-methyl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide 在 argon Dess-Martin periodinane 、 碳酸氢钠 、 二氯甲烷 、 Brine 、 magnesium sulfate 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以to afford the title compound (1.47 g, 88%) as a white foamy solid的产率得到1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-(4-formyl-phenyl)-5-methyl-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS

  摘要：

  公式（I）的化合物或其药学上可接受的衍生物：其中Z、R1、R2a、R2b、R10、R11和Rx的定义如规范所述，制备这种化合物的过程，包含这种化合物的药物组合物以及这种化合物在医学上的用途。

  公开号：

  US20090239845A1
• 作为产物：
  描述：

  1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carbonyl chloride 、 对氨基苯甲醇 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-N-[4-(hydroxyl-methyl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists

  摘要：

  We describe the discovery of a series of pyrazole amide EP1 receptor antagonists with good aqueous solubility and CNS penetration. In order to achieve solubility we investigated the incorporation of a basic group in the region of the molecule previously occupied by a carboxylic acid, which was known to be a key element of the pharmacophore. This study led to the identification of compounds such as 4h, 4j and 10b which demonstrated brain-to-blood ratios of 0.8: 1-2.0: 1 in addition to good solubility and metabolic stability. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.118

文献信息

• PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS
  申请人：Conway Elizabeth Ann

  公开号：US20090239845A1

  公开（公告）日：2009-09-24

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R 1 , R 2a , R 2b , R 10 , R 11 and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中Z、R1、R2a、R2b、R10、R11和Rx的定义如规范所述，制备这种化合物的过程，包含这种化合物的药物组合物以及这种化合物在医学上的用途。
• WO2006/114313
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS<br/>[FR] COMPOSES DE PYRAZOLE UTILISES COMME LIGANDS DES RECEPTEURS DE LA PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2006114313A1

  公开（公告）日：2006-11-02

  [EN] Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R¹ ,R^2a, R^2b, R¹⁰, R¹¹ and R^x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
  [FR] L'invention concerne des composés de formule (I) ou un dérivé pharmaceutiquement acceptable de ces composés. Dans cette formule Z, R¹, R^2a, R^2b, R¹⁰, R¹¹ et R^x sont tels que définis dans la description. L'invention concerne également un procédé de préparation de ces composés, des compositions pharmaceutiques renfermant ces composés ainsi que l'utilisation desdits composés dans un médicament.
• Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists
  作者：Adrian Hall、Andy Billinton、Alan K. Bristow、Susan H. Brown、Anita Chowdhury、Leanne Cutler、Gerard M.P. Giblin、Paul Goldsmith、Thomas G. Hayhow、Ian R. Kilford、Alan Naylor、Barry Passingham、D. Anthony Rawlings

  DOI：10.1016/j.bmcl.2008.05.118

  日期：2008.7

  We describe the discovery of a series of pyrazole amide EP1 receptor antagonists with good aqueous solubility and CNS penetration. In order to achieve solubility we investigated the incorporation of a basic group in the region of the molecule previously occupied by a carboxylic acid, which was known to be a key element of the pharmacophore. This study led to the identification of compounds such as 4h, 4j and 10b which demonstrated brain-to-blood ratios of 0.8: 1-2.0: 1 in addition to good solubility and metabolic stability. (c) 2008 Elsevier Ltd. All rights reserved.